drugset
drugset / Trial / NCT03541902

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

NCT03541902 ↗

Phase 2 Active not recruiting 32 enrolled M.D. Anderson Cancer Center Exelixis · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. This is an investigational study. Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC. The study doctor can explain how the study drugs are designed to work. Up to 84 participants will be enrolled in this study. All will take part at MD Anderson.

Timeline

Start
2018-05-15
Primary completion
2027-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule — Oral
Subject Sunitinib Small molecule — Oral

Indications

chromophobe renal cell carcinoma papillary renal cell carcinoma renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions sarcomatoid renal cell carcinoma